Diseases in which fibrosis plays a major role account for an estimated 45% of deaths in the western world

Fibrosis can affect virtually all organs and tissues. In the case of physical or vascular trauma, repairative fibrosis such as wound healing is critical for survival. However, when the fibrotic response becomes dysregulated either as an extended response to injury (e.g. cardiac fibrosis) or as a secondary response to proinflammaory cytokines/growth factors (e.g. cancer stroma) it will result in diseases with devastating pathologies.

NovoMedix has developed a series of novel orally available small molecules with wide therapeutic windows to treat fibrotic diseases. The initial targeted indication will be Liver Fibrosis with the goal of rapid delivery of this first-in-class therapy to patients. Additional indications include Heart, Lung, and Kidney fibrosis as well cancers that are highly dependent on the stroma such as pancreatic and breast.


August 12 2018 - Publication in American Journal of Physiology Heart and Circulatory Physiology Titled "A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure” highlights NovoMedix’s novel antifibrotic small molecule program that effectively prevents fibroblast activation. A lead compound reduced the formation of cardiac fibrosis and preserved cardiac function in a murine model of transaortic constriction induced heart failure with reduced ejection fraction. The unique combination of biological activities of these compounds should have significant impact not only in heart failure but in fibrotic disease that affect other major organs such as liver, lung, and kidney as well as malignant tumors that are highly dependent on the stroma such as pancreatic and breast cancer.

Get in touch